These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755 [TBL] [Abstract][Full Text] [Related]
3. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China. Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252 [TBL] [Abstract][Full Text] [Related]
4. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201 [TBL] [Abstract][Full Text] [Related]
5. Emergence of Hypervirulent ST11-K64 Wei T; Zou C; Qin J; Tao J; Yan L; Wang J; Du H; Shen F; Zhao Y; Wang H Front Public Health; 2022; 10():765624. PubMed ID: 35309213 [TBL] [Abstract][Full Text] [Related]
6. ARGONAUT-III and -V: susceptibility of carbapenem-resistant Jacobs MR; Abdelhamed AM; Good CE; Mack AR; Bethel CR; Marshall S; Hujer AM; Hujer KM; Patel R; van Duin D; Fowler VG; Rhoads DD; Six DA; Moeck G; Uehara T; Papp-Wallace KM; Bonomo RA Antimicrob Agents Chemother; 2024 Sep; 68(9):e0075124. PubMed ID: 39133021 [TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent Shi Q; Shen S; Tang C; Ding L; Guo Y; Yang Y; Wu S; Han R; Yin D; Hu F Emerg Microbes Infect; 2024 Dec; 13(1):2361007. PubMed ID: 38801099 [TBL] [Abstract][Full Text] [Related]
8. A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring Niu S; Chavda KD; Wei J; Zou C; Marshall SH; Dhawan P; Wang D; Bonomo RA; Kreiswirth BN; Chen L mSphere; 2020 Aug; 5(4):. PubMed ID: 32848008 [TBL] [Abstract][Full Text] [Related]
9. Loss and gain of ceftazidime-avibactam susceptibility in a non-carbapenemase-producing K1-ST23 hypervirulent Zhao J; Pu D; Li Z; Zhang Y; Liu X; Zhuo X; Lu B; Cao B Virulence; 2024 Dec; 15(1):2348251. PubMed ID: 38697754 [TBL] [Abstract][Full Text] [Related]
10. Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City. Manning N; Balabanian G; Rose M; Landman D; Quale J Microb Drug Resist; 2018; 24(1):35-39. PubMed ID: 28590820 [TBL] [Abstract][Full Text] [Related]
11. Reversion of KPC-114 to KPC-2 in ceftazidime-avibactam- resistant/meropenem-susceptible Pariona JGM; Vásquez-Ponce F; Becerra J; Martins-Gonçalves T; Pariona EMM; Madueño FT; Esposito F; V de Lima A; Mello Sampaio JL; Galhardo RS; Lincopan N Microbiol Spectr; 2024 Oct; 12(10):e0117324. PubMed ID: 39190636 [No Abstract] [Full Text] [Related]
12. Efficacy of ceftazidime/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli. Öztaş S; Er DK; Dündar D; Keçeli SA Acta Microbiol Immunol Hung; 2024 Jul; 71(2):110-120. PubMed ID: 38837219 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016. Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A; Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054 [TBL] [Abstract][Full Text] [Related]
14. Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam. Kazmierczak KM; Biedenbach DJ; Hackel M; Rabine S; de Jonge BL; Bouchillon SK; Sahm DF; Bradford PA Antimicrob Agents Chemother; 2016 Aug; 60(8):4490-500. PubMed ID: 27161636 [TBL] [Abstract][Full Text] [Related]
15. Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant Wu Y; Yu W; Chu X; Zhang J; Jia P; Liu X; Zhu Y; Xu Y; Yang Q Microbiol Spectr; 2024 Jun; 12(6):e0010724. PubMed ID: 38712934 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment. Wang F; Zhou Q; Yang X; Bai Y; Cui J PLoS One; 2021; 16(10):e0258426. PubMed ID: 34648556 [TBL] [Abstract][Full Text] [Related]
18. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo. Göttig S; Frank D; Mungo E; Nolte A; Hogardt M; Besier S; Wichelhaus TA J Antimicrob Chemother; 2019 Nov; 74(11):3211-3216. PubMed ID: 31365094 [TBL] [Abstract][Full Text] [Related]
19. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam. Galani I; Antoniadou A; Karaiskos I; Kontopoulou K; Giamarellou H; Souli M Clin Microbiol Infect; 2019 Jun; 25(6):763.e5-763.e8. PubMed ID: 30928562 [TBL] [Abstract][Full Text] [Related]
20. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]